Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iDuo-MM CAR-NK cells
- Development stage
- Preclinical
- Lead developer
- Fate Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
iDuo-MM CAR-NK cells are **quadruple gene-engineered induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells** designed as an off-the-shelf cell therapy for **multiple myeloma**. These cells are engineered to express: - a **chimeric antigen receptor (CAR) optimized for NK cells and targeting B-cell maturation antigen (BCMA)**, - a **high-affinity, non-cleavable CD16 Fc receptor (hnCD16)** to augment antibody-dependent cellular cytotoxicity (ADCC), - a **membrane-bound interleukin-15/IL-15 receptor fusion (IL-15RF)** for enhanced persistence and functionality, - and a **CD38 knockout** to prevent fratricide (self-killing) and improve metabolic fitness. This combination allows iDuo-MM CAR-NK cells to kill myeloma cells via direct CAR-mediated cytotoxicity and via enhanced ADCC when combined with anti-CD38 monoclonal antibodies (e.g., daratumumab). Preclinical data suggest robust cytotoxicity and durable tumor control, with potential for combination strategies in multiple myeloma therapy[1][5][7].
- Other names
- iDuo-MM CAR-NKiDuo-MM CAR-NK cells
02
Targets
FCGR3B (Fc gamma receptor III)CD38 (Cluster of Differentiation 38)BCMA (B-cell maturation antigen)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on iDuo-MM CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iDuo-MM CAR-NK cells.